BioCardia

BioCardia PP&E per Employee

The PP&E per Employee of BioCardia (BCDA) as of Nov 20, 2026 is 103,411.76 USD. In the previous year, PP&E per Employee was 121,470.59 USD — a change of -14.87% (lower).

PP&E per Employee

103,411.76USD

YoY

-14.87%

Last updated:

PP&E per Employee of BioCardia is 2022 103,411.76 USD. PP&E per Employee of BioCardia was 2021 121,470.59 USD. It decreases by -14.87% lower compared to the previous year.

The BioCardia PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2015
8,823.53 USD
Jan 1, 2016
6,529.41 USD
Jan 1, 2017
9,941.18 USD
Jan 1, 2018
8,529.41 USD
Jan 1, 2019
73,294.12 USD
Jan 1, 2020
41,882.35 USD
Jan 1, 2021
121,470.59 USD
Jan 1, 2022
103,411.76 USD
The BioCardia PP&E per Employee history
YEARPP&E per EmployeeYoY
103,411.76USD-14.87%
121,470.59USD+190.03%
41,882.35USD-42.86%
73,294.12USD+759.31%
8,529.41USD-14.20%
9,941.18USD+52.25%
6,529.41USD-26.00%
8,823.53USD+108.33%
4,235.29USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCardia Stock analysis

What does BioCardia do? BioCardia, Inc. generates revenue through its clinical-stage regenerative medicine portfolio, primarily focused on CardiAMP and CardiALLO cell therapies. The CardiAMP Cell Therapy System is in Phase III trials for ischemic systolic heart failure, targeting healthcare providers and clinical trial sponsors seeking advanced treatments for heart failure patients. CardiALLO, an allogeneic off-the-shelf mesenchymal stem cell product, is developed for broader therapeutic applications, appealing to hospitals and research institutions requiring ready-to-use regenerative solutions. The company also monetizes the Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products, which serve as complementary tools for medical professionals during therapeutic procedures. CardiAMP and CardiALLO are positioned as innovative therapeutic candidates targeting heart failure and regenerative medicine segments, with CardiAMP advancing toward potential commercialization in late-stage trials. The Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products cater to interventional cardiology and surgical markets, providing specialized equipment for clinicians. BioCardia's revenue streams are derived from partnerships with clinical trial sponsors and direct sales of medical devices to healthcare facilities, focusing on cardiovascular and regenerative medicine applications. The company's business model relies on developing and commercializing cell therapies and medical devices, with CardiAMP leading the portfolio in late-stage development. CardiALLO serves as a complementary allogeneic product, while the Helix and Morph products support procedural needs in cardiology. Revenue is anticipated from future commercialization of CardiAMP post-trial success and from ongoing sales of the Helix and Morph systems to medical institutions. BioCardia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioCardia stock

PP&E per Employee of BioCardia is 103,411.76 USD in 2022.

PP&E per Employee of BioCardia changed from 121,470.59 USD to 103,411.76 USD, representing a -14.87% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee BioCardia since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's BioCardia historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — BioCardia

All Key Metrics — BioCardia